Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Saturday, May 31, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, NP/PAs, and other HCPs involved in the treatment and management of ovarian cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the role of molecular and biomarker testing—including BRCA, homologous recombination deficiency, and FRα—in guiding personalized treatment decisions for patients with ovarian cancer
- Analyze recent clinical trial data on PARP inhibitors (PARPi), antibody-drug conjugates (ADCs), and novel combination therapies to optimize treatment strategies
- Integrate evolving evidence into clinical practice to optimize maintenance therapy and sequencing of novel therapies in ovarian cancer management
- Develop strategies to proactively manage and mitigate treatment-related toxicities associated with PARPi, ADCs, and immune checkpoint inhibitors in ovarian cancer
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here